Novel cilengitide-based cyclic RGD peptides as αvβ 3 integrin inhibitors

• Published in: Bioorganic & medicinal chemistry letters 2020-04, Vol.30 (8), p.127039
• Main Authors: Meena, Chhuttan L, Singh, Dharmendra, Weinmüller, Michael, Reichart, Florian, Dangi, Abha, Marelli, Udaya Kiran, Zahler, Stefan, Sanjayan, Gangadhar J
• Format: Article
• Language: English
• Subjects: Dose-Response Relationship, Drug; Humans; Integrin alphaVbeta3 - antagonists & inhibitors; Integrin alphaVbeta3 - metabolism; Molecular Structure; Peptides, Cyclic - chemical synthesis; Peptides, Cyclic - chemistry; Peptides, Cyclic - pharmacology; Structure-Activity Relationship
• ISSN: 1464-3405

In this letter, we report a series of five new RGD-containing cyclic peptides as potent inhibitors to αvβ integrin protein. We have incorporated various unnatural lipophilic amino acids into the cyclic RGD framework of cilengitide, which is selective for αvβ integrin. All the newly synthesized cyclic peptides were evaluated in vitrosolid phase binding assay and investigated for their bindingbehaviourtowards integrin subtypes. All the cyclic peptides were synthesized in excellent yield following solution-phase coupling strategy. The cyclic RGD peptides 1a-e exhibited IC of 9.9, 5.5, 72, 11 and 3.3 nM, respectively, towardsαvβ integrin protein. This finding offers further opportunities for the introduction unusual amino acids into the cyclic peptide framework of cilengitide.